This has not been the case in most cases. In a 2005 WHO report, it was found that many developing countries have not incorporated INTO their legislation the flexibilities of TRIPS (compulsory licences, parallel imports, data protection restrictions, use of broad research and other exceptions to patentability, etc.) to the extent that this is permitted under Doha.  It may also clarify or clarify the provisions of the agreement. In addition, the agreement provides for certain fundamental principles, such as the treatment of the most favoured national and state states, as well as certain general rules, to ensure that procedural difficulties encountered in acquiring or maintaining the gains and others do not destroy the material benefits that the agreement should have. The obligations under the agreement also apply to all Member States, but developing countries have a longer period of time to include them. Specific transitional provisions apply in a situation where a developing country currently offers no patent protection for products in the field of medicines. All WTO agreements (with the exception of some multi-lateral agreements) apply to all WTO members. Members accepted all agreements as one package with one signature, which made them one company in the jargon. However, members may choose to implement laws that offer broader protection than the agreement provides, provided that the additional protection is not contrary to the provisions of the agreement. Data exclusivity and other provisions on TRIPS more are often encouraged under free trade agreements between developed and developing countries.
But the question of what should be patented is left to countries. The agreement only stipulates that patents must be granted for new, inventive and useful inventions – but it does not define these concepts. For example, deciding whether a new formulation (which produces, for example, a hairy version of a drug that used to come in powder form) or a new combination (combining two or more existing molecules into a new pill) would merit a new 20-year patent is a prerogative of countries and is not determined by WTO texts. Countries should therefore determine, taking into account their own social and economic conditions, the types of inventions that deserve to be patented in the field of medicines. Some governments, such as Brazil, Thailand or India, have done so. In today`s world, for many patients, this choice can be a matter of life and death. The management of trade unions created under the various conventions is centralised by the WIP secretariat, the International Bureau. The International Bureau also has international registration services in the field of patents, trademarks, designs and appellations of origin. WIPO also deals with development cooperation for developing countries through advice, training and documents. Trips-plus conditions, which impose standards beyond TRIPS, have also been verified.  These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers.